Zealand Pharma A/S
ZEAL
Classement en actions
#5528
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Prix de l'action
$35.14
Capitalisation boursière
$2.44B
Changement (1 jour)
-1.95%
Changement (1 an)
-50.93%
Pays
DK
Échange Zealand Pharma A/S (ZEAL)
Catégorie
Healthcare
Capitalisation boursière de Zealand Pharma A/S(ZEAL)
Capitalisation boursière: $2.44B
En October 2026, Zealand Pharma A/S a une capitalisation boursière de $2.44B. Cela fait de Zealand Pharma A/S la 5528th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Zealand Pharma A/S du 2013 au 2026
ZEAL par rapport au top 5 des plus populaires stocks
